The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Recruiting · NCT06330012 · Interventional (participants receive a specific treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
GeoMx data analysis with clinical outcome
What this trial is about
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Who can take part
Age range
No age limits stated
Sex
Female
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Exclusion criteria
- TNBC breast cancer
- Hormone receptor positive breast cancer
- Non-available FFPE samples
- Treated except T-Dxd
Where it is running
1 location listed.
- Ji-Yeon Kim - Seoul, South Korea